Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors
Aromatase inhibitors (AI), which decrease circulating estradiol concentrations in post-menopausal women, are associated with toxicities that limit adherence. Approximately one-third of patients will tolerate a different AI after not tolerating the first. We report the effect of crossover from exemestane to letrozole or vice versa on patient-reported outcomes (PROs) and whether the success of crossover is due to lack of estrogen suppression.
Post-menopausal women enrolled on a prospective trial initiating AI therapy for early-stage breast cancer were randomized to exemestane or letrozole. Those that discontinued for intolerance were offered protocol-directed crossover to the other AI after a washout period. Changes in PROs, including pain [Visual Analog Scale (VAS)] and functional status [Health Assessment Questionnaire (HAQ)], were compared after 3 months on the first versus the second AI. Estradiol and drug concentrations were measured.
Eighty-three patients participated in the crossover protocol, of whom 91.3% reported improvement in symptoms prior to starting the second AI. Functional status worsened less after 3 months with the second AI (HAQ mean change AI #1: 0.2 [SD 0.41] vs. AI #2: −0.05 [SD 0.36]; p = 0.001); change in pain scores was similar between the first and second AI (VAS mean change AI #1: 0.8 [SD 2.7] vs. AI #2: −0.2 [SD 2.8]; p = 0.19). No statistical differences in estradiol or drug concentrations were found between those that continued or discontinued AI after crossover.
Although all AIs act via the same mechanism, a subset of patients intolerant to one AI report improved PROs with a different one. The mechanism of this tolerance remains unknown, but does not appear to be due to non-adherence to, or insufficient estrogen suppression by, the second AI.
KeywordsAromatase inhibitors Arthralgia Patient outcome assessment Crossover Quality of life
- 3.Burstein HJ, Lacchetti C, Anderson H et al (2016) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol 34:1689–1701. doi:10.1200/JCO.2015.65.9573 CrossRefPubMedGoogle Scholar
- 7.Yardley D, Green NB, Papish S, et al (2009) Rheumatologic Evaluation of Adjuvant Letrozole in Post-Menopausal Breast Cancer Patients Discontinuing Anastrozole Due to Grade 2-3 Arthralgia—Myalgia. In: San Antonio Breast Cancer Symp. p Cancer Res 2009;69(24 Suppl):Abstract nr 805Google Scholar
- 8.Renshaw L, McHugh R, Williams L (2007) Comparison of joint problems reported by patients in a randomized adjuvant trial of anastrozole and letrozole. In: Breast Can Res Treat. p 106(Suppl 1):S108–S109. Abstract 2072Google Scholar
- 16.Carpenter JS, Andrykowski MA, Wilson J, et al Psychometrics for two short forms of the center for epidemiologic studies-depression scale. Issues Ment Health Nurs 19:481–94Google Scholar
- 17.Stafford L, Judd F, Gibson P et al (2014) Comparison of the hospital anxiety and depression scale and the center for epidemiological studies depression scale for detecting depression in women with breast or gynecologic cancer. Gen Hosp Psychiatry 36:74–80. doi:10.1016/j.genhosppsych.2013.08.010 CrossRefPubMedGoogle Scholar
- 19.Farrar JT, Pritchett YL, Robinson M et al (2010) The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain 11:109–118. doi:10.1016/j.jpain.2009.06.007 CrossRefPubMedGoogle Scholar
- 23.Briot K, Tubiana-Hulin M, Bastit L et al (2010) Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120:127–134. doi:10.1007/s10549-009-0692-7 CrossRefPubMedGoogle Scholar